CompletedNCT00423878
Antipsychotic medicines and metabolic health in schizophrenia
About this title
Read the official source — NCT00423878Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Colton and 27 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJanuary 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 215
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00423878
- Official title
Show the full official title
Clinical Management of Metabolic Problems in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Colton · Palo Alto · New Haven
25 more locations
- Boca Raton
- Miami
- Atlanta
- Augusta
- Iowa City
- Wichita
- Shreveport
- Glen Burnie
- Boston
- Fall River
- Worcester
- Detroit
- Minneapolis
- St Louis
- Albuquerque
- New York
- Rochester
- Butner
- Chapel Hill
- Charlotte
- Cincinnati
- Philadelphia
- Dallas
- Houston
- San Antonio
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Did this study involve medication?
Yes. The study involved medication, including Risperidone, Olanzapine, Quetiapine and Aripiprazole.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
